Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.
Koistinen P, Räty R, Itälä M, Jantunen E, Koivunen E, Nousiainen T, Pelliniemi TT, Remes K, Ruutu T, Savolainen ER, Siitonen T, Silvennoinen R, Volin L, Elonen E; Finnish Leukaemia Group. Koistinen P, et al. Among authors: volin l. Eur J Haematol. 2007 Jun;78(6):477-86. doi: 10.1111/j.1600-0609.2007.00846.x. Epub 2007 Mar 28. Eur J Haematol. 2007. PMID: 17391337
Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters.
Syrjälä H, Ohtonen P, Kinnunen U, Räty R, Elonen E, Nousiainen T, Jantunen E, Remes K, Itälä-Remes M, Silvennoinen R, Koistinen P; Finnish Leukemia Group. Syrjälä H, et al. Eur J Clin Microbiol Infect Dis. 2010 Oct;29(10):1211-8. doi: 10.1007/s10096-010-0984-1. Epub 2010 Jun 17. Eur J Clin Microbiol Infect Dis. 2010. PMID: 20556469 Free article.
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
Kolonen A, Sinisalo M, Huhtala H, Rimpiläinen J, Rintala H, Sankelo M, Koivunen E, Silvennoinen R, Räty R, Ruutu T, Volin L, Porkka K, Jantunen E, Nousiainen T, Kuittinen T, Penttilä K, Pyörälä M, Säily M, Koistinen P, Kauppila M, Itälä-Remes M, Ollikainen H, Rauhala A, Kairisto V, Pelliniemi TT, Elonen E; Finnish Leukemia Group. Kolonen A, et al. Among authors: volin l. Eur J Haematol. 2022 Sep;109(3):257-270. doi: 10.1111/ejh.13805. Epub 2022 Jun 14. Eur J Haematol. 2022. PMID: 35634931 Clinical Trial.
234 results